Albendazole Dosing for Ascariasis
For ascariasis, administer albendazole 400 mg as a single oral dose for both adults and children, regardless of weight. 1
Dosing Specifics
The 2025 UK guidelines for eosinophilia management explicitly recommend for ascariasis treatment: albendazole PO 400 mg as a single dose 1. This same dose applies universally:
- Adults: 400 mg single dose
- Children: 400 mg single dose (no weight-based adjustment needed)
- Administration: Take with food to enhance absorption 2
The FDA label confirms this dosing but provides weight-stratified guidance primarily for other conditions (hydatid disease, neurocysticercosis), not specifically for ascariasis 2.
Efficacy Evidence
Single-dose albendazole demonstrates excellent efficacy against ascariasis, with cure rates consistently exceeding 90%:
- Multiple guideline sources confirm cure rates of approximately 93-98% for ascariasis with single-dose therapy 1
- A 2020 Cochrane review analyzing 30 RCTs (6,442 participants) found an illustrative cure rate of 93.0% with single-dose albendazole versus 16.1% with placebo 3
- Egg reduction rates (ERR) reach 96-100% across studies 3
- A 2014 randomized controlled trial in Gabon demonstrated 85% cure rate and 93.8% ERR with single-dose albendazole for Ascaris 4
Important Clinical Considerations
Single dose is sufficient for ascariasis - Unlike hookworm (which may require 3 days) or trichuriasis (which shows poor response even with extended regimens), ascariasis responds excellently to single-dose therapy 1, 4.
No dose adjustment by weight for ascariasis - While the FDA label describes weight-based dosing for hydatid disease and neurocysticercosis (15 mg/kg/day divided twice daily for patients <60 kg), this does NOT apply to ascariasis treatment 2. The guideline evidence consistently supports 400 mg single dose regardless of patient size 1.
Tablet administration - Tablets may be crushed or chewed and swallowed with water if swallowing whole is difficult, particularly in children 2.
Take with food - Albendazole absorption increases up to 5-fold when administered with a fatty meal (approximately 40 grams fat content), significantly improving bioavailability 2.
Alternative Regimens
If albendazole is unavailable, equally effective alternatives include:
- Mebendazole 500 mg single dose (cure rate 96.9%) 1
- Ivermectin 200 μg/kg single dose (cure rate 90.2%) 1
The 2025 guidelines show no significant difference in efficacy between these three options for ascariasis 1.
Safety Profile
Albendazole is well-tolerated with minimal adverse events. Commonly reported effects include nausea, vomiting, abdominal pain, diarrhea, headache, and fever, but these occur at similar rates across all anthelmintic groups 3. No serious adverse events were reported in the Cochrane review of 30 trials 3.
Special Populations
Pregnancy: Albendazole poses potential fetal risk; pregnant women should be counseled about risks 2.
Lactation: Very low levels are excreted in breastmilk, likely compatible with breastfeeding 1.
Children aged 12-24 months: For empirical treatment of eosinophilia, expert consultation is recommended, though the standard 400 mg dose remains appropriate for confirmed ascariasis in children >24 months 1.